NCT04603989View on ClinicalTrials.gov

A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

November 13, 2020

Study Completion Date

November 13, 2020

Conditions
Influenza
Interventions
DRUG

HNC042 for Injection

HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg

DRUG

Placebo Comparator

Placebo , Intravenous route , multiple ascending doses

Trial Locations (1)

510000

Jiang Yuting, Guangzhou

All Listed Sponsors
collaborator

Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

INDUSTRY

lead

Guangzhou Henovcom Bioscience Co. Ltd.

INDUSTRY

NCT04603989 - A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics | Biotech Hunter | Biotech Hunter